Leading Austrian Clinic, Klinik Pirawarth, Provides Positive Feedback on its First Nexstim NBT® System for Treatment of Depression and Pain
Helsinki, Finland: 18 June 2019 – Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD) – announces that the company’s first NBT® system sold in Austria has generated positive feedback from its use in treating patients with depression and pain.
The system was sold to Klinik Pirawarth, one of the most experienced centres in Austria utilising promising new techniques for non-invasive brain stimulation. Every year about 4500 patients are referred to Klinik Pirawarth, which comprises a neurological, orthopaedic and psychosomatic department. The clinic purchased the Nexstim NBT® system earlier this year to use the SmartFocusTM TMS technology to treat mainly depression and chronic neuropathic pain patients.
More info on Nexstim‘s website